Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Authors:
- 18 September 2008
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 23 (1) , 162-169
Abstract
Antiangiogenic drugs are currently tested in haematological malignancies. As these drugs target different angiogenic regulators, and as cancers are inherently heterogeneous, a detailed characterization of angiogenesis in individual cancers is needed. Hence, we measured bone marrow microvessel density (MVD), plasma concentrations of eight angiogenesis-related parameters and the expression in blood mononuclear cells of 40 angiogenesis-related mRNAs in 93 patients with haematological neoplasias (acute myeloid leukaemia; chronic lymphatic leukaemia; multiple myeloma (MM); or non-Hodgkin's lymphoma (NHL)) before start and after completion of cancer therapy. Compared with healthy individuals, the patients had significantly increased bone marrow MVD, especially patients with advanced stage disease. A novel finding was that patients with NHL also had increased bone marrow MVD. The plasma levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6 and IL-8 were significantly increased. VEGF levels were highest in those who did not achieve complete remission after cancer therapy. The mRNA expression of IL-8 was upregulated 15-fold. Our data show that patients with haematological malignancies have increased bone marrow MVD; hence, supporting the notion that bone marrow angiogenesis plays a role in the pathogenesis and progression of these cancers. VEGF, IL-6 and IL-8 seem to contribute to the malignant phenotype.Keywords
This publication has 39 references indexed in Scilit:
- Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cellsBiochemical and Biophysical Research Communications, 2008
- Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factorThrombosis and Haemostasis, 2008
- Angiogenesis and antiangiogenic therapy in hematologic malignanciesCritical Reviews in Oncology/Hematology, 2007
- Monocyte/macrophage infiltration in tumors: modulators of angiogenesisJournal of Leukocyte Biology, 2006
- Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parametersAmerican Journal of Hematology, 2006
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- Angiogenesis and Hemostasis in Hematological NeoplasiasCurrent Drug Targets, 2005
- Guidelines on the diagnosis and management of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2004
- Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemiaBlood, 2002
- Tissue Factor Pathway Inhibitor Inhibits Endothelial Cell Proliferation via Association with the Very Low Density Lipoprotein ReceptorJournal of Biological Chemistry, 2001